Cancer clinical trials in the region Île-de-France

666 currently recruiting clinical trials
Region Île-de-France

Phase 3 Brain tumors / Central nervous system tumors #NCT06556563 #2024-513550-30-00
Required histologic types
Gliomas
Required histologic sub types
Glioblastoma
Required number of previous lines of therapy
None
Required previous treatments
Surgery Chemotherapy Radiotherapy Radiochemotherapy
Excluded previous treatments
Systemic Treatment-Naive Immunotherapy
5 recruiting sites
NovoCure GmbH
Phase 3 Brain tumors / Central nervous system tumors #NCT06388733 #2024-513077-48-00
Required histologic types
Gliomas
Required histologic sub types
Glioblastoma
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded genetic anomalies
IDH1/2
Excluded previous treatments
Chemotherapy Radiotherapy Radiochemotherapy TTFields Other targeted therapy
10 recruiting sites
Ivy Brain Tumor Center
Phase 3 Brain tumors / Central nervous system tumors #NCT05902169 #2023-505829-14-00
Required histologic types
Gliomas
Required histologic sub types
Glioblastoma
Required number of previous lines of therapy
1
Required previous treatments
Surgery Immunotherapy Chemotherapy Radiotherapy
Excluded genetic anomalies
BRAF IDH1/2 NTRK-1/2/3
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
CarThera
Phase 3 Brain tumors / Central nervous system tumors #NCT05904119
Required histologic types
Gliomas
Required histologic sub types
Glioblastoma
Required number of previous lines of therapy
1
Required previous treatments
Surgery Radiochemotherapy
Excluded genetic anomalies
IDH1/2
Excluded previous treatments
Systemic Treatment-Naive
10 recruiting sites
EORTC - Organisation Européenne pour la Recherche et le Traitement du Cancer
Phase 3 Brain tumors / Central nervous system tumors #NCT05476939 #2014-001929-32
Required histologic types
Gliomas
Required histologic sub types
Diffuse midline glioma grade IV
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded previous treatments
Chemotherapy Radiotherapy
33 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3 Brain tumors / Central nervous system tumors #NCT05476939 #2014-001929-32
Phase inclusion - gliomes diffus de la ligne médiane non-DIPG
Required histologic types
Gliomas
Required histologic sub types
Diffuse midline glioma grade IV
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Excluded previous treatments
Chemotherapy Radiotherapy
33 recruiting sites
Gustave Roussy, Campus du cancer, Grand Paris
Phase 3 Lymphoma #NCT06006117 #2022-501810-77-00
Required histologic types
B cell lymphoma
Required histologic sub types
Marginal zone lymphoma
Required central nervous system lesions
None
Required renal function statuses
> 60 ml/min 50-60 ml/min 30-50 ml/min
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Chemotherapy Targeted therapy Monoclonal antibodies
Excluded previous treatments
Systemic Treatment-Naive Bispecific T-cell engager antibodies Allogeneic stem cell transplant
23 recruiting sites
The Lymphoma Academic Research Organisation (LYSARC)
Phase 3 Brain tumors / Central nervous system tumors #NCT04702581
Required histologic types
Gliomas
Required histologic sub types
Oligodendroglioma grade II
Required genetic anomalies
IDH1/2
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive Surgery
Excluded previous treatments
Chemotherapy Radiotherapy
14 recruiting sites
Hospices Civils de Lyon
Phase 3 Sarcoma and GIST #NCT07218926 #2025-522229-37-00
Required histologic types
GIST
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
KIT PDGFRA
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
GlaxoSmithKline
Phase 3 Endometrial cancer #NCT07044336 #2024-518777-34-00
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
13 recruiting sites
AstraZeneca